Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid ...

The FDA recently approved mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

Learn how Dupixent helps diverse eczema patients and why inclusive clinical trials are vital for fair healthcare.

Dupilumab use in asthma linked to higher lymphoma risk, especially T/NK cell types, though overall mortality was lower, new ...

Discover a study where results suggest a statistically significant association between dupilumab and psoriasis, although the clinical impact may be limited.

The Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...